BIOLASE

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

BIOLASE reports strong Q1 performance, eyes profitability through market growth

BIOLASE's Q1 2024 earnings reflect a robust performance with growth in sales and improved financial metrics. The company's strategic focus on accelerating dental laser adoption and operational enhancements position it well for future success. While challenges exist in achieving profitability, BIOLASE's opportunities in the dental market and growth initiatives offer a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1984 and is headquartered in Lake Forest, CA.

LAKE FOREST, Calif. , Sept. 13, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the pricing of an underwritten public offering of 75,000 units (the "Units"), with each Unit consisting of one share of BIOLASE's Series J Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $100.00 per share (the "Series J Convertible Preferred Stock"), and one warrant (the "Warrants") to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock.

BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

BIOLASE, Inc. (NASDAQ:BIOL ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Todd Kehrli - EVC Group John Beaver - President & Chief Executive Officer Jennifer Bright - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Ed Woo - Ascendiant Capital Operator Good day, and welcome to the BIOLASE Second Quarter 2023 Financial Results Conference Call. Please note this call is being recorded.

BIOLASE, Inc. (BIOL) Q2 2023 Earnings Call Transcript

Continues to Experience Positive Momentum and Expects to Achieve Improved Net Income and Positive Adjusted EBITDA for the Second Half of 2023 LAKE FOREST, Calif. , Aug. 10, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the second quarter ended June 30, 2023.

BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEAR

Allarity Therapeutics

G Medical Innovations Holdings Ltd

Penumbra

ZyVersa Therapeutics Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off In August

LAKE FOREST, Calif. , Aug. 2, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release second quarter 2023 financial and operating results on Thursday, August 10, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m.

BIOLASE TO REPORT SECOND QUARTER 2023 RESULTS ON AUGUST 10, 2023

COMMON STOCK WILL BEGIN TRADING ON SPLIT-ADJUSTED BASIS ON JULY 28, 2023 LAKE FOREST, Calif. , July 26, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced that it held a special meeting of its stockholders on July 20, 2023 where the Company's stockholders granted the Board of Directors the discretion to effect a reverse stock split of the Company's common stock at a ratio between 1-to-2 and 1-to-100.

BIOLASE ANNOUNCES 1-FOR-100 REVERSE STOCK SPLIT

Innovative Technology Continues to be Recognized by Industry Peers LAKE FOREST, Calif. , July 17, 2023 /PRNewswire/ -- BIOLASE , Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced that its Epic Hygiene  dental laser, the only hygiene dental laser cleared by the U.S. Food and Drug Administration (FDA) for laser bacterial reduction, has been awarded Cellerant's 2023 Best of Class Hygiene Award.

BIOLASE EPIC HYGIENE DENTAL LASER RECEIVES PRESTIGIOUS CELLERANT BEST OF CLASS HYGIENE AWARD

Strategically Located Facility To Provide Best-in-Class Education & Training Programs LAKE FOREST, Calif. , June 15, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced plans to open a state-of-the-art training facility, "BIOLASE Education Center" with an Open House scheduled for 5 PM Pacific time on Thursday,  July 27, 2023.

BIOLASE Announces Grand Opening of Training Facility to Reach Wider Universe of Dental Practitioners; First-Hand Experience Using Leading Dental Laser Technology Expected to Generate Increased Revenue Opportunities

LAKE FOREST, Calif. , June 14, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that President and Chief Executive Officer, John Beaver and Chief Financial Officer, Jennifer Bright, have been invited to participate in the 2023 Virtual Healthcare Conference, presented by Maxim Group LLC and hosted by M-Vest, on June 20th to 22nd.

BIOLASE TO PARTICIPATE IN MAXIM GROUP'S 2023 VIRTUAL HEALTHCARE CONFERENCE HOSTED BY M-VEST ON JUNE 20TH - 22ND

LAKE FOREST, Calif. , June 14, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced an arrangement with Pet Dental Services (PDS), the #1 non-anesthetic pet dental provider in the country, to integrate BIOLASE's diode laser technology.

BIOLASE INTEGRATES DIODE LASER TECHNOLOGY WITH PET DENTAL SERVICES

LAKE FOREST, Calif., June 5, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly-designated Series I Preferred Stock, par value $0.001 per share, for each outstanding share of BIOLASE common stock held of record as of 5:00 p.m.

BIOLASE ANNOUNCES DISTRIBUTION OF SERIES I PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCK

LAKE FOREST, Calif. , June 5, 2023 /PRNewswire/ -- BIOLASE , Inc. (NASDAQ: BIOL ), a global leader in dental lasers, is taking the necessary steps to optimize operations to capitalize on the rising business momentum for its market-leading dental lasers.

BIOLASE Takes Steps to Improve Operating Efficiency as the Company Pursues Sales and Profitability Goals

LAKE FOREST, Calif. , May 26, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the closing of its previously announced underwritten public offering of 175,000 units (the "Units"), with each Unit consisting of one share of BIOLASE's Series H Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $50.00 per share (the "Series H Convertible Preferred Stock"), and one warrant (the "Warrants") to purchase one-half of one (0.50) share of Series H Convertible Preferred Stock.

BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants

LAKE FOREST, Calif. , May 24, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the pricing of an underwritten public offering of 175,000 units (the "Units"), with each Unit consisting of one share of BIOLASE's Series H Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $50.00 per share (the "Series H Convertible Preferred Stock"), and one warrant (the "Warrants") to purchase one-half of one (0.50) share of Series H Convertible Preferred Stock.

BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants

Biolase (NASDAQ: BIOL ) stock is taking a beating on Friday following the release of its earnings report for the first quarter of 2023. The bad news for investors in BIOL stock is the company's earnings per share of -18 cents for the period.

Why Is Biolase (BIOL) Stock Down 13% Today?

Educational and Training Programs Introducing Broader Community of Dentists to Experience Industry-Leading Dental Lasers for the First Time LAKE FOREST, Calif. , May 11, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the first quarter ended March 31, 2023.

BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023

LAKE FOREST, Calif. , May 4, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release first quarter 2023 financial and operating results on Thursday, May 11, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m.

BIOLASE TO REPORT FIRST QUARTER 2023 RESULTS ON MAY 11, 2023

Bed Bath & Beyond

China Jo-Jo Drugstores Holdings

How to evaluate penny stocks using risk management techniques The post Penny Stock Risk Assessment: Evaluating Potential Investments  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stock Risk Assessment: Evaluating Potential Investments

BIOLASE, Inc. (NASDAQ:BIOL ) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Todd Kehrli - IR John Beaver - President and CEO Jennifer Bright - CFO Conference Call Participants Bruce Jackson - The Benchmark Company Frank Takkinen - Lake Street Capital Markets Anthony Vendetti - Maxim Group Edward Woo - Ascendiant Capital Operator Greetings. Welcome to the BIOLASE 2022 Fourth Quarter and Full Year Financial Results Call.

BIOLASE, Inc. (BIOL) Q4 2022 Earnings Call Transcript

LAKE FOREST, Calif. , March 28, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the fourth quarter and full year ended December 31, 2022.

BIOLASE DELIVERS 24% REVENUE GROWTH IN 2022 AS GO-TO-MARKET STRATEGIES GAIN MOMENTUM; GUIDES FOR AT LEAST 25% REVENUE GROWTH AND PROFITABILITY IN 2023

Lab Session W ill Provide Firsthand Experience using the Company's Award-Winning Waterlase All-Tissue Laser Annual Tequila & Tongue Ties Conference to be held in Scottsdale, AZ, on April 21-22, 2023 LAKE FOREST, Calif. , March 14, 2023 /PRNewswire/ -- BIOLASE, Inc.

BIOLASE GATHERS KEY OPINION LEADERS AND DENTAL CLINICIANS TO HIGHLIGHT TONGUE-TIE TREATMENT BEST PRACTICES

LAKE FOREST, Calif. , March 13, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release fourth quarter and full year 2022 financial and operating results on Tuesday, March 28, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m.

BIOLASE TO REPORT FOURTH QUARTER AND FULL YEAR 2022 RESULTS ON MARCH 28, 2023

New Episodes W ill Feature Engaging Stories from Clinicians About the Benefits of Laser Technology in Dentistry LAKE FOREST, Calif. , March 6, 2023 /PRNewswire/ --  BIOLASE, Inc.

BIOLASE PLANS TO LAUNCH SEASON 2 OF ITS POPULAR PODCAST SERIES

LAKE FOREST, Calif. , Feb. 27, 2023 /PRNewswire/ --   BIOLASE , Inc. (NASDAQ: BIOL), the global leader in dental lasers and a company continually focused on improving the dental ecosystem, has launched a new e-commerce website for its U.S. customers.

BIOLASE LAUNCHES E-COMMERCE SITE TO ENHANCE POSITIVE USER EXPERIENCE AND STREAMLINE THE PURCHASING PROCESS TO CREATE GREATER EFFICIENCIES FOR DENTAL PRACTITIONERS

The new handpiece uses advanced, proprietary technology to  deliver faster healing and quicker recovery for skin-resurfacing patients LAKE FOREST, Calif. , Feb. 23, 2023 /PRNewswire/ -- BIOLASE, Inc.

News for BIOLASE Stock (BIOL)